Phenotypic Assays to Identify Agents That Induce Reactive Gliosis

A Counter-Screen to Prioritize Compounds for Preclinical Animal Studies

Samuel R. Beckerman, Joaquin E. Jimenez, Yan Shi, Hassan Al-Ali, John Bixby, Vance Lemmon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Astrocyte phenotypes change in a process called reactive gliosis after traumatic central nervous system (CNS) injury. Astrogliosis is characterized by expansion of the glial fibrillary acidic protein (GFAP) cytoskeleton, adoption of stellate morphologies, and differential expression of some extracellular matrix molecules. The astrocytic response immediately after injury is beneficial, but in the chronic injury phase, reactive astrocytes produce inhibitory factors (i.e., chondroitin sulfate proteoglycans [CSPGs]) that limit the regrowth of injured axons. There are no drugs that promote axon regeneration or functional recovery after CNS trauma in humans. To develop novel therapeutics for the injured CNS, we screened various libraries in a phenotypic assay to identify compounds that promote neurite outgrowth. However, the effects these compounds have on astrocytes are unknown. Specifically, we were interested in whether compounds could alter astrocytes in a manner that mimics the glial reaction to injury. To test this hypothesis, we developed cell-based phenotypic bioassays to measure changes in (1) GFAP morphology/localization and (2) CSPG expression/immunoreactivity from primary astrocyte cultures. These assays were optimized for six-point dose-response experiments in 96-well plates. The GFAP morphology assay is suitable for counter-screening with a Z-factor of 0.44±0.03 (mean±standard error of the mean; N=3 biological replicates). The CSPG assay is reproducible and informative, but does not satisfy common metrics for a "screenable" assay. As proof of principle, we tested a small set of hit compounds from our neurite outgrowth bioassay and identified one that can enhance axon growth without exacerbating the deleterious characteristics of reactive gliosis.

Original languageEnglish (US)
Pages (from-to)377-388
Number of pages12
JournalAssay and Drug Development Technologies
Volume13
Issue number7
DOIs
StatePublished - Sep 1 2015

Fingerprint

Gliosis
Astrocytes
Chondroitin Sulfate Proteoglycans
Glial Fibrillary Acidic Protein
Nervous System Trauma
Axons
Central Nervous System
Biological Assay
Wounds and Injuries
Cytoskeleton
Neuroglia
Libraries
Extracellular Matrix
Regeneration
Phenotype
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Phenotypic Assays to Identify Agents That Induce Reactive Gliosis : A Counter-Screen to Prioritize Compounds for Preclinical Animal Studies. / Beckerman, Samuel R.; Jimenez, Joaquin E.; Shi, Yan; Al-Ali, Hassan; Bixby, John; Lemmon, Vance.

In: Assay and Drug Development Technologies, Vol. 13, No. 7, 01.09.2015, p. 377-388.

Research output: Contribution to journalArticle

@article{06037d5904a64f5f9c882586b777afe9,
title = "Phenotypic Assays to Identify Agents That Induce Reactive Gliosis: A Counter-Screen to Prioritize Compounds for Preclinical Animal Studies",
abstract = "Astrocyte phenotypes change in a process called reactive gliosis after traumatic central nervous system (CNS) injury. Astrogliosis is characterized by expansion of the glial fibrillary acidic protein (GFAP) cytoskeleton, adoption of stellate morphologies, and differential expression of some extracellular matrix molecules. The astrocytic response immediately after injury is beneficial, but in the chronic injury phase, reactive astrocytes produce inhibitory factors (i.e., chondroitin sulfate proteoglycans [CSPGs]) that limit the regrowth of injured axons. There are no drugs that promote axon regeneration or functional recovery after CNS trauma in humans. To develop novel therapeutics for the injured CNS, we screened various libraries in a phenotypic assay to identify compounds that promote neurite outgrowth. However, the effects these compounds have on astrocytes are unknown. Specifically, we were interested in whether compounds could alter astrocytes in a manner that mimics the glial reaction to injury. To test this hypothesis, we developed cell-based phenotypic bioassays to measure changes in (1) GFAP morphology/localization and (2) CSPG expression/immunoreactivity from primary astrocyte cultures. These assays were optimized for six-point dose-response experiments in 96-well plates. The GFAP morphology assay is suitable for counter-screening with a Z-factor of 0.44±0.03 (mean±standard error of the mean; N=3 biological replicates). The CSPG assay is reproducible and informative, but does not satisfy common metrics for a {"}screenable{"} assay. As proof of principle, we tested a small set of hit compounds from our neurite outgrowth bioassay and identified one that can enhance axon growth without exacerbating the deleterious characteristics of reactive gliosis.",
author = "Beckerman, {Samuel R.} and Jimenez, {Joaquin E.} and Yan Shi and Hassan Al-Ali and John Bixby and Vance Lemmon",
year = "2015",
month = "9",
day = "1",
doi = "10.1089/adt.2015.654",
language = "English (US)",
volume = "13",
pages = "377--388",
journal = "Assay and Drug Development Technologies",
issn = "1540-658X",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Phenotypic Assays to Identify Agents That Induce Reactive Gliosis

T2 - A Counter-Screen to Prioritize Compounds for Preclinical Animal Studies

AU - Beckerman, Samuel R.

AU - Jimenez, Joaquin E.

AU - Shi, Yan

AU - Al-Ali, Hassan

AU - Bixby, John

AU - Lemmon, Vance

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Astrocyte phenotypes change in a process called reactive gliosis after traumatic central nervous system (CNS) injury. Astrogliosis is characterized by expansion of the glial fibrillary acidic protein (GFAP) cytoskeleton, adoption of stellate morphologies, and differential expression of some extracellular matrix molecules. The astrocytic response immediately after injury is beneficial, but in the chronic injury phase, reactive astrocytes produce inhibitory factors (i.e., chondroitin sulfate proteoglycans [CSPGs]) that limit the regrowth of injured axons. There are no drugs that promote axon regeneration or functional recovery after CNS trauma in humans. To develop novel therapeutics for the injured CNS, we screened various libraries in a phenotypic assay to identify compounds that promote neurite outgrowth. However, the effects these compounds have on astrocytes are unknown. Specifically, we were interested in whether compounds could alter astrocytes in a manner that mimics the glial reaction to injury. To test this hypothesis, we developed cell-based phenotypic bioassays to measure changes in (1) GFAP morphology/localization and (2) CSPG expression/immunoreactivity from primary astrocyte cultures. These assays were optimized for six-point dose-response experiments in 96-well plates. The GFAP morphology assay is suitable for counter-screening with a Z-factor of 0.44±0.03 (mean±standard error of the mean; N=3 biological replicates). The CSPG assay is reproducible and informative, but does not satisfy common metrics for a "screenable" assay. As proof of principle, we tested a small set of hit compounds from our neurite outgrowth bioassay and identified one that can enhance axon growth without exacerbating the deleterious characteristics of reactive gliosis.

AB - Astrocyte phenotypes change in a process called reactive gliosis after traumatic central nervous system (CNS) injury. Astrogliosis is characterized by expansion of the glial fibrillary acidic protein (GFAP) cytoskeleton, adoption of stellate morphologies, and differential expression of some extracellular matrix molecules. The astrocytic response immediately after injury is beneficial, but in the chronic injury phase, reactive astrocytes produce inhibitory factors (i.e., chondroitin sulfate proteoglycans [CSPGs]) that limit the regrowth of injured axons. There are no drugs that promote axon regeneration or functional recovery after CNS trauma in humans. To develop novel therapeutics for the injured CNS, we screened various libraries in a phenotypic assay to identify compounds that promote neurite outgrowth. However, the effects these compounds have on astrocytes are unknown. Specifically, we were interested in whether compounds could alter astrocytes in a manner that mimics the glial reaction to injury. To test this hypothesis, we developed cell-based phenotypic bioassays to measure changes in (1) GFAP morphology/localization and (2) CSPG expression/immunoreactivity from primary astrocyte cultures. These assays were optimized for six-point dose-response experiments in 96-well plates. The GFAP morphology assay is suitable for counter-screening with a Z-factor of 0.44±0.03 (mean±standard error of the mean; N=3 biological replicates). The CSPG assay is reproducible and informative, but does not satisfy common metrics for a "screenable" assay. As proof of principle, we tested a small set of hit compounds from our neurite outgrowth bioassay and identified one that can enhance axon growth without exacerbating the deleterious characteristics of reactive gliosis.

UR - http://www.scopus.com/inward/record.url?scp=84940643937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940643937&partnerID=8YFLogxK

U2 - 10.1089/adt.2015.654

DO - 10.1089/adt.2015.654

M3 - Article

VL - 13

SP - 377

EP - 388

JO - Assay and Drug Development Technologies

JF - Assay and Drug Development Technologies

SN - 1540-658X

IS - 7

ER -